Dr. Sandeep Kumar, Formulation Development manager, Colorcon, sheds light on how selecting an excipient in early formulation development is critical to developing a robust scalable SOD formulation and can help the transition from capsule to tablet.
EPM fired some quick questions with Juan Guerra, president of International Business Group at AmerisourceBergen, to learn about the increasing market for cold chain products and the future of the biopharma supply chain.
Co-founded by the cancer institute Gustave Roussy, Paris-Saclay University and the French company Clevexel Pharma, Graegis Pharmaceuticals plans to start proof-of-concept clinical trials in 2023 in the prevention of radiation-induced dermatitis.
Shafique Virani, chief corporate development officer and interim chief medical officer, Recursion, delves into digital transformation within drug discovery and the power of AI-enabled platforms in the future of therapeutics.
In this case study, IMA Active has recently upgraded its continuous tablet-coating solution with the installation of OMRON's vision system equipped with a high-speed colour camera and dome light.
Jeong Jin-hyeok, associated director of Aseptic Filling, at Samsung Biologics, examines the lessons learned following the onset of COVID-19 and highlights how CDMO flexibility is helping to hail in an era of new therapeutic modalities.
GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and Research, NUS, NTU Singapore and SITT to boost Singapore's biologics manufacturing capabilities.
Allen Burgenson, associate director, Global Subject Matter (SME) Testing, Lonza, discusses the a more sustainable route to future-proof testing and quality control in pharma.
EPM asks Sandra Hernandez, Global Clinical Flow Marketing Manager, Beckman Coulter Life Sciences, about her journey into the field of medical technology, what it's like being a woman in STEM, and some of the biggest challenges in the industry.
Experts from Watson-Marlow Fluid Technology Solutions and National Institute for Bioprocessing Research and Training (NIBRT) discuss the advantages of single-use technologies in CGT manufacturing platforms.
Russell Green, director product growth for Drug Discovery and Synthetic Biology, Automata, describes three reasons why automation should become an integral part of the vaccine development process.
Dr. Klaus Pollinger and Dr. Martina Breuer, Aenova Group, explore the challenges of development and commercial manufacturing of oral solid dosage forms, from a CDMO perspective.
